Drugs moving into the clinic: 35

By Mike Nagle

- Last updated on GMT

The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Sponsor Name Indication Mechanism
Synta Pharmaceuticals STA-9090 Oncology " heat shock protein 90 (Hsp90) inhibitor unrelated to geldanamycin or its family of related compounds, such as 17-AAG"
Lexicon Pharmaceuticals LX2931 Rheumatoid arthritis and other autoimmune disorders "Inhibits key enzyme in sphingolipid pathway, which controls lymphocyte circulation and trafficking to peripheral sites in the body during an inflammatory response. N.B. IND submitted to US FDA"
Trubion Pharamceuticals TRU-016 Oncology - B-cell malignancies: non-Hodgkin's lymphoma and chronic lymphocytic leukaemia (CLL) "Depletes B cells by binding to a cell surface protein found in high-levels exclusively on B cells and to a lesser extent on a subpopulation of T cells and myeloid cells. The precise function of the target is not known, though experiments suggest that it plays an important role in B-cell regulation.N.B. IND submitted to US FDA"
Lundbeck Lu AA47070 Parkinson's disease and other neurological disorders adenosine receptor inhibitor
Metastatix MSX-122 Oncology CXCR4 inhibitor

Related topics: Preclinical Research

Related news

Show more